Background: A protrusion array device (PAD) configured with hollow dissolvable microneedles was loaded with the JVRS-100 adjuvant or JVRS-100 combined with commercial Fluzone. The studies were designed to establish if adjuvant or adjuvant/vaccine could be administered via PAD patches. Methods: JVRS-100, Fluzone, or JVRS-100/Fluzone were loaded onto PAD patches and administered at day 0 and 14. At day 28 responses were assessed by HAI and ELISA (IgG, IgG1, and IgG2). Separate cohorts of mice were vaccinated intramuscularly (IM) with Fluzone and JVRS-100-containing patches were placed over the site of vaccination to see if intradermal administration of JVRS-100 would adjuvant IM vaccination. Results: The administration of JVRS-100 in addition to Fluzone stimulated a response greater than Fluzone alone patches as measured by geometric mean titer (EC50) for IgG (4.8x104 vs. 1.6x104) and IgG2 (4.5x103 vs 6.0x102). IgG1 titers were elevated in the Fluzone only group compared with JVRS-100/Fluzone (8.3x103 vs. 1.9x103). Administration of JVRS-100-containing patches over IM Fluzone vaccination increased IgG (3.7x105 vs. 2.2x105) and IgG2a (1.5x105 vs. 9.0x104). IgG1 titers were elevated in the Fluzone-only group compared with JVRS-100/Fluzone (1.5x105 vs. 2.9x105). HAI levels correlated with antibody titer levels for all groups. Conclusion: The antibody response from both studies indicate that the TH1 bias for JVRS-100 is retained as a dry PAD patch and intradermal administration over IM vaccination or combined for ID vaccination.